Last reviewed · How we verify
chemotherapy (CHOP)
CHOP is a combination chemotherapy regimen that uses four cytotoxic agents to kill rapidly dividing cancer cells through multiple mechanisms of DNA damage and cell cycle disruption.
CHOP is a combination chemotherapy regimen that uses four cytotoxic agents to kill rapidly dividing cancer cells through multiple mechanisms of DNA damage and cell cycle disruption. Used for Non-Hodgkin lymphoma, diffuse large B-cell lymphoma, Hodgkin lymphoma, Other lymphoid malignancies.
At a glance
| Generic name | chemotherapy (CHOP) |
|---|---|
| Also known as | CHOP |
| Sponsor | Sun Yat-sen University |
| Drug class | Combination chemotherapy regimen |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
CHOP combines cyclophosphamide (alkylating agent), doxorubicin (topoisomerase II inhibitor), vincristine (microtubule inhibitor), and prednisone (corticosteroid) to attack cancer cells through complementary pathways. This multi-drug approach increases efficacy against lymphomas by targeting different phases of the cell cycle and overwhelming cellular repair mechanisms. The regimen has been a standard-of-care treatment for decades, particularly in hematologic malignancies.
Approved indications
- Non-Hodgkin lymphoma, diffuse large B-cell lymphoma
- Hodgkin lymphoma
- Other lymphoid malignancies
Common side effects
- Neutropenia
- Anemia
- Thrombocytopenia
- Nausea and vomiting
- Alopecia
- Mucositis
- Cardiotoxicity (doxorubicin-related)
- Infection
Key clinical trials
- Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma (PHASE3)
- Obinutuzumab With or Without Umbralisib, Lenalidomide, or Combination Chemotherapy in Treating Patients With Relapsed or Refractory Grade I-IIIa Follicular Lymphoma (PHASE2)
- Testing the Addition of a New Anti-cancer Drug, Venetoclax, to Usual Chemotherapy for High Grade B-cell Lymphomas (PHASE2, PHASE3)
- Rituximab and Combination Chemotherapy With or Without Lenalidomide in Treating Patients With Newly Diagnosed Stage II-IV Diffuse Large B Cell Lymphoma (PHASE2)
- Testing the Addition of an Anti-Cancer Drug, Glofitamab, to the Usual Chemotherapy Treatment (Alternating R-CHOP/R-DHAP) for Previously Untreated Mantle Cell Lymphoma (PHASE1)
- A Phase III Trial Comparing Tisagenlecleucel to Standard of Care (SoC) in Adult Participants With r/r Follicular Lymphoma (PHASE3)
- A Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma Patients (PHASE3)
- S0016 Combination Chemotherapy With Monoclonal Antibody Therapy in Newly Diagnosed Non-Hodgkin's Lymphoma (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- chemotherapy (CHOP) CI brief — competitive landscape report
- chemotherapy (CHOP) updates RSS · CI watch RSS
- Sun Yat-sen University portfolio CI